Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Health Catalyst (HCAT) Current Deferred Revenue (2018 - 2025)

Health Catalyst (HCAT) has disclosed Current Deferred Revenue for 8 consecutive years, with $58.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Deferred Revenue rose 12.69% year-over-year to $58.8 million, compared with a TTM value of $58.8 million through Sep 2025, up 12.69%, and an annual FY2024 reading of $53.3 million, down 4.43% over the prior year.
  • Current Deferred Revenue was $58.8 million for Q3 2025 at Health Catalyst, down from $67.0 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $71.9 million in Q1 2025 and bottomed at $51.6 million in Q1 2021.
  • Average Current Deferred Revenue over 5 years is $58.6 million, with a median of $56.5 million recorded in 2021.
  • The sharpest move saw Current Deferred Revenue soared 61.01% in 2021, then fell 5.88% in 2023.
  • Year by year, Current Deferred Revenue stood at $57.6 million in 2021, then dropped by 4.34% to $55.1 million in 2022, then grew by 1.19% to $55.8 million in 2023, then dropped by 4.43% to $53.3 million in 2024, then rose by 10.4% to $58.8 million in 2025.
  • Business Quant data shows Current Deferred Revenue for HCAT at $58.8 million in Q3 2025, $67.0 million in Q2 2025, and $71.9 million in Q1 2025.